The Oncology Institute, Inc. (STLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, The Oncology Institute, Inc. (STLN) has a cash flow conversion efficiency ratio of -0.479x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($11.94 Million) by net assets ($-24.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see STLN stock market capitalisation for the company's overall valuation and market capitalisation.
The Oncology Institute, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how The Oncology Institute, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for The Oncology Institute, Inc. for real-time trading data and today's change.
The Oncology Institute, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of The Oncology Institute, Inc. ranked by their cash flow conversion efficiency. Review The Oncology Institute, Inc. free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wanxiang Doneed Co Ltd
SHG:600371
|
-0.012x |
|
Flexium Interconnect Inc
TW:6269
|
-0.005x |
|
W olf Photoelectric Technology Ltd
SHE:002962
|
0.015x |
|
Chongqing Wangbian Electric (Group) Corp. Ltd.
SHG:603191
|
N/A |
|
ZheJiang ZhongKe Magnetic Co. Ltd. A
SHE:301141
|
N/A |
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
0.159x |
|
Zheshang Development Group Co Ltd
SHE:000906
|
-0.164x |
|
Nanjing Railway New Technology Co.Ltd.
SHE:301016
|
-0.016x |
Annual Cash Flow Conversion Efficiency for The Oncology Institute, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of The Oncology Institute, Inc. from 2022 to 2025. Also see how large is The Oncology Institute, Inc.'s balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-15.72 Million | $-24.59 Million | 1.564x | +121.15% |
| 2024-12-31 | $3.59 Million | $-26.54 Million | -7.394x | -1061.11% |
| 2023-12-31 | $57.02 Million | $-36.31 Million | -0.637x | -27.02% |
| 2022-12-31 | $123.17 Million | $-61.76 Million | -0.501x | -- |
About The Oncology Institute, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educatio… Read more